[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT02471170":3,"trial-entities:NCT02471170":60,"trial-summary:NCT02471170":64},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":16,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":26,"secondary_outcomes":30,"sex":31,"minimum_age":32,"maximum_age":16,"healthy_volunteers":33,"eligibility_criteria":34,"std_ages":40,"locations":43,"central_contacts":53,"overall_officials":54,"references":58,"see_also_links":59},"NCT02471170","UPCC 02215","Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases","ENROLLING_BY_INVITATION","2035-01-01","2026-06","2026-07-02","2015-09-10","Abramson Cancer Center at Penn Medicine","OTHER",true,"The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.",null,[18],"Pancreatic Diseases",[],"OBSERVATIONAL",[],{"count":23,"type":24},100,"ESTIMATED",[],[27],{"measure":28,"timeFrame":29},"Collection of blood and tissue samples from subjects with pancreatic diseases","3 years",[],"ALL","18 Years",false,{"inclusion":35,"exclusion":38,"raw_text":39},[36,37],"The subject must be under evaluation and\u002For treatment for a pancreatic disease","The subject must be under evaluation and\u002For treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples. 2. The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf 3. The subject must be 18 years of age or older",[],"Inclusion Criteria:\n\n1. The subject must be a patient at the Hospital of the University of Pennsylvania\n\n   * The subject must be under evaluation and\u002For treatment for a pancreatic disease\n   * The subject must be under evaluation and\u002For treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.\n2. The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf\n3. The subject must be 18 years of age or older\n\nExclusion Criteria:\n\n1. The subject or acceptable surrogate does not provide informed consent\n2. Subject is a prisoner\n3. Subject is under 18 years of age",[41,42],"ADULT","OLDER_ADULT",[44],{"facility":45,"city":46,"state":47,"zip":48,"country":49,"geoPoint":50},"Abramson Cancer Center of the University of Pennsylvania","Philadelphia","Pennsylvania","19104","United States",{"lat":51,"lon":52},39.95238,-75.16362,[],[55],{"name":56,"affiliation":12,"role":57},"Peter O'Dwyer, MD","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":61,"biomarkers":63},[62],"Pancreatic Disorder",[],{"nct_id":4,"found":33,"summary":16,"prompt_version":16}]